

Study of the Antimicrobial Potential of Bacteria found in Natural Resources

Svetlana Noskova¹ , Svetlana Ivanova^{2,3*} , Alexander Prosekov⁴ ,
Lyubov Dyshlyuk^{2,5} , Elena Ulrikh⁶ , Margarita Shevchenko¹ ,
Olga Babich¹  and Stanislav Sukhikh^{1,5} 

¹Institute of Living Systems, Immanuel Kant Baltic Federal University, A. Nevskogo Street 14, Kaliningrad, 236016, Russia.

²Natural Nutraceutical Biotesting Laboratory, Kemerovo State University, Krasnaya Street 6, Kemerovo, 650043, Russia.

³Department of General Mathematics and Informatics, Kemerovo State University, Krasnaya Street, 6, Kemerovo 650043, Russia.

⁴Laboratory of Biocatalysis, Kemerovo State University, Krasnaya Street 6, Kemerovo, 650043, Russia.

⁵Department of Bionanotechnology, Kemerovo State University, Krasnaya Street 6, Kemerovo, 650043, Russia.

⁶Kuzbass State Agricultural Academy, Markovtseva street, 5, Kemerovo 650056, Russia.

Abstract

Bacteriocins are of great interest as potential antimicrobial agents against various types of bacteria, fungi, and viruses. Isolates of microorganisms derived from natural sources were used in the current study, including lactic acid bacteria and other antagonistic microorganisms. The species of the microorganisms were determined using 16S rDNA and ITS nrDNA analyses. *E. coli*, *S. enterica*, *S. aureus*, *P. aeruginosa*, *B. mycoides*, *A. faecalis*, *P. vulgaris*, *S. flexneri*, *L. monocytogenes*, *C. albicans*, *A. flavus*, and *P. citrinum* were used as pathogenic and opportunistic strains. It was found that 11 strains of antagonistic microorganisms have significant antimicrobial activity against all pathogenic and opportunistic microorganisms. The antimicrobial properties of these microorganisms are currently under study.

Keywords: Bacteriocins, Lactic acid bacteria, Antagonistic microorganisms, Isolates, Antimicrobial activity, Pathogenic microorganisms

*Correspondence: pavvm2000@mail.ru

(Received: March 27, 2021; accepted: May 06, 2021)

Citation: Noskova S, Ivanova S, Prosekov A, et al. Study of the Antimicrobial Potential of Bacteria found in Natural Resources. *J Pure Appl Microbiol.* 2021;15(2):759-771. doi: 10.22207/JPAM.15.2.28

© The Author(s) 2021. **Open Access.** This article is distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

INTRODUCTION

The discovery of antibiotics was a major breakthrough in treating infectious diseases, significantly improving the quality of life and longevity worldwide. However, after several years of antibiotic use, resistance to antimicrobials emerged. Since then, its spread has become a severe health problem.¹ Gram-positive and gram-negative bacteria are increasingly showing multidrug resistance to the main antibiotics and drugs used in clinical practice, such as drug-resistant methicillin-resistant *Staphylococcus aureus*, resulting in higher morbidity and mortality than usual.²⁻⁴ Multidrug resistance of enterococci to vancomycin has also been reported. Drug resistance has placed a burden on patient health and the economies of hospitals and communities, indicating the need for developing new antibiotic drugs. Additionally, rational use of existing antibiotics could alleviate this problem.⁵

Many natural resources, including plants, animals, and microorganisms, have been studied.⁶ Combining chemical and biotechnology tools, these resources can provide several compounds that may prove to be promising antimicrobial agents.⁷⁻⁹ Bacteria have also been studied in natural resources for their ability to resist other bacteria. The discovery of the first bacteriocin in 1925 made it possible to develop an entire field of research, including several studies aimed at identifying novel antimicrobial compounds of microbial origin in the subsequent decades.¹⁰ Bacteriocins are of increasing interest as potential antibacterial agents against various bacteria, fungi, and viruses.¹¹⁻¹³ Naturally resistant structures such as bacterial biofilm can also be similarly exploited.¹⁴⁻¹⁵ These natural peptides are synthesized by ribosomes and produced by bacteria living in competitive microbial environments and can be used to kill other bacteria, especially those that are closely related to the biofilm producers.¹⁶⁻¹⁹ Consequently, the considerable variety of bacteriocins provides a wide range of activity.²⁰⁻²² Ribosomes produce bacteriocins and convert them into molecules unlike synthetic antibiotics,²³ such as lipopeptides and glycopeptides.²³

Although bacteriocins are produced in a gram-positive form,²⁴ most registered bacteriocins are gram-negative,²⁵ especially *Lactobacillus*.^{12,26} These microbial compounds are predominantly

bacterial in origin, and some studies have shown that virtually any bacteria can produce bacteriocins.^{27,28} Due to the diversity of bacteria producing bacteriocins, numerous bacteriocins have been identified, and some bacteria can produce more than one bacteriocin.²⁹ These bacteriocins can be used in various fields of biotechnology, industry, and pharmaceuticals.^{22,30,31}

The food industry is one of the main areas for potential bacteriocin use.³² Due to their probiotic properties, some LABs and their metabolites are generally considered safe for use in the food industry.³³ Therefore, LABs can inhibit the biological capacity of competing flora,³⁰ especially that of foodborne pathogens such as *Listeria monocytogenes*, *Clostridium*, *Staphylococcus*, and *E. coli*. Lactic acid bacteria (LAB) can be used in multiple ways, including fermentation and food preservation.³⁴⁻³⁶ As bacteriocins are readily degraded by proteolytic enzymes, they can be considered safe for human use, e.g., proteases in the gastrointestinal tract of mammals.³³

Unlike antibiotics, bacteriocins can act on particular pathogens without affecting other symbiotic flora.³⁷ The European Union has now authorized the use of the bacteriocin nisin as a food preservative; by the World Health Organization nisin has been registered as a food additive under the number E234³⁸

However, the development of bacteriocins as biological preservatives is still of great interest. Bacteriocins have been widely studied, particularly in relation to the food industry. For example, it has been shown that bacteriocins can improve the biological safety of vegetable products³⁹, and they can be utilized in effective packaging.⁴⁰ Various methods can be used to add bacteriocins to foods. Bacteriocins can be added via direct inoculation or indirectly as lactic acid bacteria that produce bacteriocin products, as purified bacteriocins for food preservation, and the addition of LAB-containing fermentation products as food components.⁴¹⁻⁴²

Another important potential use of bacteriocins is in combating antibiotic-resistant bacteria.^{12,43} Drug-resistant bacteria reduce antibiotic efficacy, a major problem in societies due to the challenges in developing alternative antibiotic treatment methods.^{5,44-47} Due to the presence of a survival factor in bacteria,

Table 1. Results of the identification of microorganisms depending on the isolation sources

Isolate	Isolation source	Species	Isolate	Isolation source	Species
A	I	<i>B. subtilis</i>	K	III	<i>P. pentosaceus</i>
B	I	<i>P. glabrum</i>	L	II	<i>L. casei</i>
C	II	<i>P. lagena</i>	M	II	<i>L. fermentum</i>
D	I	<i>P. koreensis</i>	N	I	<i>B. hypermegas (M. hypermegale)</i>
E	III	<i>P. ochrochloron</i>	O	I	<i>B. ruminicola(P. ruminicola)</i>
F	IV	<i>L. lactis</i>	P	III	<i>P.s damnosus</i>
G	IV	<i>L. plantarum</i>	Q	I	<i>Bacteroides paurosaccharolyticus</i>
H	III	<i>L. mesenteroides</i>	R	V	<i>H. profundi</i>
I	I	<i>P. acidilactici</i>	S	III	<i>G. stearothermophilus</i>
J	II	<i>L. mesenteroides</i>	T	I	<i>B. caldotenax</i>

I - soil; II – fruits and vegetables; III -natural water bodies; IV – food wastes; V – wastewater




Fig. 1. Phylogenetic tree showing the relative position of fungi isolates based on ITS nrDNA (a) and on 16S rDNA (b) sequences, using the neighbor-joining method

Table 2. Physiological and biochemical properties of microorganisms isolated from natural sources of the Kemerovo region

Substance	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T
Control	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gentiobiose	-	-	-	-	-	-	+	+	-	+	-	-	+	+	+	-	-	-	-	-
Erythritol	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
L-rhamnose	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-fructose	-	-	-	-	+	+	+	+	-	+	-	+	+	+	+	+	+	-	-	+
D-sucrose	+	+	+	+	+	+	+	+	-	+	-	+	+	+	+	+	+	-	-	+
D-arabinose	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Potassium gluconate	-	-	-	-	-	-	+	+	-	+	-	+	+	+	+	+	+	-	-	-
Methyl- α -D-xylopyranoside	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Esculin	-	-	-	-	+	+	+	+	-	+	-	-	+	+	+	+	+	-	-	+
Amygdalin	-	-	-	-	-	-	+	+	-	+	-	-	+	+	+	+	+	-	-	+
Salicin	-	+	+	+	-	-	+	+	-	+	-	-	+	+	+	+	+	+	-	-
L-sorbose	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Glycogen	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dulcitol	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inositol	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-glucose	+	+	+	-	+	+	+	+	-	+	-	+	+	+	+	+	+	+	-	+
D-sorbitol	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-raffinose	-	+	+	+	-	-	+	+	-	+	-	+	+	+	+	+	+	-	-	-
Methyl- α -D-glucopyranoside	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-adonitol	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-cellobiose	-	+	+	-	-	-	+	+	-	+	-	+	+	+	+	+	+	+	-	+
D-melezitose	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-lactose	+	+	+	-	+	+	-	+	-	+	-	+	+	+	+	+	+	-	-	-
Starch	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-arabitol	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inulin	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-fucose	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-trehalose	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Xylitol	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Potassium 2-ketogluconate	-	-	-	-	-	-	+	+	-	+	-	-	-	-	-	-	-	-	-	-
D-turansose	-	-	-	-	-	-	-	+	+	+	-	+	+	+	+	+	+	+	+	+
D-melibiose	-	-	-	-	+	+	-	-	+	+	-	-	-	-	-	-	-	-	-	-
D-lyxose	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-mannitol	+	+	+	-	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
L-arabinose	-	+	+	+	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Glycerol	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
D-xylitol	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Methyl- α -D-mannopyranoside	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

+ – positive result; - – negative result. Isolates A – *B. subtilis*; B – *P. glabrum*; C – *P. lagena*; D – *P. koreensis*; E – *P. ochrochloron*; F – *L. lactis*; G – *L. plantarum*; H – *L. mesenteroides*; I – *P. acidilactici*; J – *L. mesenteroides*; K – *P. pentosaceus*; L – *L. casei*; M – *L. fermentum*; N – *B. hypermegas*; O – *B. ruminalis*; P – *P. damnosus*; Q – *B. paurosaccharolyticus*; R – *H. profundus*; S – *G. stearothermophilus*; T – *B. caldotenax*.

Russia). Additionally, M21 medium with analyzed carbohydrate (10 g/L) and bromocresol purple dye (BCP; 32 mg/L) were used. Sugar utilization was confirmed by the color change of the colonies and nutrient medium to yellow.

The ability of bacteria to degrade esculin was determined using a medium consisting of 0.5% casein peptone, 0.3% meat extract, 0.05% iron citrate, 0.1% esculin, and 1.5% agar 1.5 at pH 6.6. Microorganisms were cultivated by incubation for 12 h at 37 °C. For esculin fermentation, medium darkening around the colonies and loss of fluorescence were observed.

Pathogenic microorganisms

Test strains of pathogenic microorganisms were purchased from the State Collection of Pathogenic Microorganisms and Cell Cultures (GKPM-Obolensk, Russia). Pathogenic effects were determined using *E. coli* ATCC 25922, *S. enterica* ATCC 14028, *S. aureus* ATCC 25923, *P. aeruginosa* B6643, *B. mycoides* EMTC 9, *A. faecalis* EMTC 1882, *P. vulgaris* ATCC 63, *P. vulgaris* ATCC 7644, *C. albicans* EMTC 34, *A. flavus* ATCC 9643, and *P. citrinum* ATCC 9849.

Cultivation of test microorganism strains

Media for cultivating pathogenic microorganisms were prepared immediately




Fig. 2. Results of determination of antimicrobial activity against test-cultures I – *E. coli*; II – *S. enterica*; III – *S. aureus*; IV – *P. aeruginosa*; V – *B. mycoides*; VI – *A. faecalis*; VII – *P. vulgaris*; VIII – *S. flexneri*; IX – *L. monocytogenes*; X – *C. albicans*; XI – *A. flavus*; XII – *P. citrinum* in a liquid nutrient medium isolates of microorganisms: K1 – control (culture medium without any additions); K2 – ciprofloxacin; isolates A – *B. subtilis*; B – *P. glabrum*; C – *P. lagena*; D – *P. koreensis*; E – *P. ochrochloron*; F – *L. lactis*; G – *L. plantarum*; H – *L. mesenteroides*; I – *P. acidilactici*; J – *L. mesenteroides*; K – *P. pentosaceus*; L – *L. casei*; M – *L. fermentum*; N – *B. hypermegas*; O – *B. ruminicola*; P – *P. damnosus*; Q – *B. paurosaccharolyticus*; R – *H. profundi*; S – *G. stearothermophilus*; T – *B. caldotenax*. Test-cultures I – *E. coli*; II – *S. enterica*; III – *S. aureus*; IV – *P. aeruginosa*; V – *B. mycoides*; VI – *A. faecalis*; VII – *P. vulgaris*; VIII – *S. flexneri*; IX – *L. monocytogenes*; X – *C. albicans*; XI – *A. flavus*; XII – *P. citrinum*

Table 3. Results of determining the antimicrobial activity of microorganisms isolated from natural sources

Sample	Lysis zone diameter, mm											
	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII
Control 1	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
Control 2	21.0±1.1	24.0±1.2	19.0±1.0	22.0±1.1	25.0±1.3	23.0±1.2	20.0±1.0	22.0±1.1	24.0±1.2	18.0±0.9	25.0±1.33	21.0±1.1
A	18.0±0.9	20.0±1.0	17.0±0.9	20.0±1.0	22.0±1.1	20.0±1.0	17.0±0.9	18.0±0.9	19.0±1.0	15.0±0.8	21.0±1.1	15.0±0.8
B	0.0±0.0	0.0±0.0	5.0±0.3	0.0±0.0	0.0±0.0	0.0±0.0	7.0±0.4	4.0±0.2	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
C	6.0±0.3	10.0±0.5	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	8.0±0.4	0.0±0.0	0.0±0.0	4.0±0.2	5.0±0.3
D	12.0±0.6	5.0±0.3	18.0±0.9	0.0±0.0	0.0±0.0	17.0±0.9	15.0±0.8	10.0±0.5	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
E	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	6.0±0.3	0.0±0.0	0.0±0.0	4.0±0.2	0.0±0.0	0.0±0.0	0.0±0.0
F	20.0±1.0	22.0±1.1	17.0±0.9	21.0±1.1	24.0±1.2	21.0±1.1	18.0±0.9	20.0±1.0	21.0±1.1	16.0±0.8	23.0±1.2	19.0±1.0
G	19.0±1.0	18.0±0.9	15.0±0.8	19.0±1.0	22.0±1.1	21.0±1.1	17.0±0.9	20.0±1.0	23.0±1.2	16.0±0.8	22.0±1.1	18.0±0.9
H	17.0±0.9	20.0±1.0	16.0±0.8	19.0±1.0	22.0±1.1	20.0±1.0	18.0±0.9	19.0±1.0	21.0±1.1	15.0±0.8	21.0±1.1	18.0±0.9
I	20.0±1.0	21.0±1.1	17.0±0.9	19.0±1.0	23.0±1.2	21.0±1.1	18.0±0.9	19.0±1.0	21.0±1.1	16.0±0.8	24.0±1.2	18.0±0.9
J	15.0±0.8	18.0±0.9	14.0±0.7	17.0±0.9	20.0±1.0	17.0±0.9	15.0±0.8	16.0±0.8	20.0±1.0	13.0±0.7	20.0±1.0	18.0±0.9
K	21.0±1.1	20.0±1.0	17.0±0.9	19.0±1.0	24.0±1.2	22.0±1.1	18.0±0.9	18.0±0.9	21.0±1.1	16.0±0.8	24.0±1.2	19.0±1.0
L	18.0±0.9	19.0±1.0	15.0±0.8	10.0±0.5	20.0±1.0	17.0±0.9	15.0±0.8	17.0±0.9	22.0±1.1	16.0±0.8	22.0±1.1	17.0±0.9
M	15.0±0.8	18.0±0.9	14.0±0.7	19.0±1.0	21.0±1.1	17.0±0.9	15.0±0.8	16.0±0.8	21.0±1.1	15.0±0.8	20.0±1.0	18.0±0.9
N	12.0±0.6	10.0±0.5	0.0±0.0	14.0±0.7	0.0±0.0	9.0±0.5	11.0±0.6	13.0±0.7	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
O	7.0±0.4	11.0±0.6	0.0±0.0	12.0±0.6	0.0±0.0	7.0±0.4	10.0±0.5	15.0±0.8	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
P	17.0±0.9	22.0±1.1	16.0±0.8	20.0±1.0	23.0±1.2	19.0±1.0	18.0±0.9	21.0±1.1	20.0±1.0	16.0±0.8	21.0±1.1	18.0±0.9
Q	15.0±0.8	13.0±0.7	0.0±0.0	16.0±0.8	0.0±0.0	12.0±0.6	14.0±0.7	17.0±0.9	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0
R	0.0±0.0	0.0±0.0	11.0±0.6	0.0±0.0	14.0±0.7	0.0±0.0	0.0±0.0	0.0±0.0	10.0±0.5	0.0±0.0	0.0±0.0	0.0±0.0
S	20.0±1.0	22.0±1.1	18.0±0.9	19.0±1.0	22.0±1.1	20.0±1.0	18.0±0.9	21.0±1.1	19.0±1.0	16.0±0.8	24.0±1.2	18.0±0.9
T	18.0±0.9	23.0±1.2	17.0±0.9	20.0±1.0	21.0±1.1	22.0±1.1	19.0±1.0	21.0±1.1	23.0±1.2	15.0±0.8	20.0±1.0	17.0±0.9

Control 1 – culture medium without any additions; control 2 - Ciprofloxacin; isolates A – *B. subtilis*; B – *P. glabrum*; C – *P. lagena*; D – *P. koreensis*; E – *P. ochrochloron*; F – *L. lactis*; G – *L. plantarum*; H – *L. mesenteroides*; I – *P. acidilactici*; J – *L. mesenteroides*; K – *P. pentosaceus*; L – *L. casei*; M – *L. fermentum*; N – *B. hypermegas*; O – *B. rumicola*; P – *P. damnosus*; Q – *B. paurosaccharolyticus*; R – *H. profundi*; S – *G. stearothermophilus*; T – *B. caldotenax*. Test-cultures I – *E. coli*; II – *S. enterica*; III – *S. aureus*; IV – *P. aeruginosa*; V – *B. mycoides*; VI – *A. faecalis*; VII – *P. vulgaris*; VIII – *S. flexneri*; IX – *L. monocytogenes*; X – *C. albicans*; XI – *A. flavus*; XII – *P. citrinum*.

before testing. Bacterial strains were cultivated for 24 h at 30–37 °C in special media⁵¹. The optical density and number of bacteria were determined at 595 nm.

Screening of isolated microorganisms for antimicrobial activity

Screening for the detection of microorganisms with antagonistic properties was carried out using the spot method according to Lucke and Schillinger with some modifications⁵⁰. Briefly, the cultures were placed on plates (1.2% agar) and incubated for 24 h at 30 °C to release metabolites and multiply bacteria. Approximately 5 × 10⁷ CFU/mL of indicator strains important in food industry (*E. coli*, *S. enterica*, *S. aureus*, *P. aeruginosa*, *B. mycoides*, *A. faecalis*, *S. flexneri*, *L. monocytogenes*, and *C. albicans* and *P. citrinum*) were inoculated into 100 mL of soft trypticase soy agar containing 0.7% agar and poured over a plate in which the isolated LAB were grown. After a 24-hour incubation at 37 °C, the inhibition

of microorganisms from the edge of the zone was measured using a caliper and expressed in millimeters.

Statistical analysis

Experiments were performed in three sequences, experimental values were expressed as mean ± standard error, and statistical processing was performed using Microsoft Office Excel 2007 (Microsoft Corporation, Redmont, WA, USA) and Statistica 10.0 (StatSoft, Tulsa, OK, USA). Equality of means was tested using the median test and the nonparametric Kruskal-Wallis test; if p d” 0.05, then the differences were considered significant.

RESULTS

Identification of microorganisms based on 16S rDNA sequencing is presented in Table 1. The LAB position according to the 16S rDNA and ITS nrDNA sequences is shown in the phylogenetic tree. *Bordetella pertussis* and *Saccharomyces cerevisiae* were investigated separately using

Table 4. Statistical analysis results

Isolates	Test cultures											
	I	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII
A	-	-	+	+	+	+	+	+	+	+	+	+
B	-	-	-	-	-	-	-	-	-	-	-	-
C	-	-	-	-	-	-	-	-	-	-	-	-
D	-	-	+	-	-	-	+	-	-	-	-	-
E	-	-	-	-	-	-	-	-	-	-	-	-
F	+	+	+	+	+	+	+	+	+	+	+	+
G	+	+	+	+	+	+	+	+	+	+	+	+
H	+	+	+	+	+	+	+	+	+	+	+	+
I	+	+	+	+	+	+	+	+	+	+	+	+
J	-	+	+	+	+	+	+	+	+	+	+	+
K	+	+	+	+	+	+	+	+	+	+	+	+
L	+	+	+	+	+	+	+	+	+	+	+	+
M	-	+	+	+	+	+	+	+	+	+	+	+
N	-	-	-	-	-	-	±	+	-	-	-	-
O	-	-	-	-	-	-	±	+	-	-	-	-
P	-	+	+	+	+	+	+	+	+	+	+	+
Q	-	-	-	+	±	-	±	+	-	-	-	-
R	-	-	-	-	-	-	-	-	-	-	-	-
S	+	+	+	+	+	+	+	+	+	+	+	+
T	+	+	+	+	+	+	+	+	+	+	+	+

-+” no statistically significant differences in values in comparison with the antibiotic; --” no statistically significant differences in values in comparison with the control; «±» - statistically significant differences in values in comparison with both antibiotic and control. Test-cultures I – *E. coli*; II – *S. enterica*; III – *S. aureus*; IV – *P. aeruginosa*; V – *B. mycoides*; VI – *A. faecalis*; VII – *P. vulgaris*; VIII – *S. flexneri*; IX – *L. monocytogenes*; X – *C. albicans*; XI – *A. flavus*; XII – *P. citrinum*.

MEGA-5; the starting position for 1,000 replicas is shown at the nodes of the phylogenetic tree. The scale bar corresponds to 0.05 units of the number of base substitutions per site. The phylogenetic trees are shown in Figure 1.

The ability to ferment various carbohydrates, including sugars, alcohols, and organic acids, underlies the distinguishing characteristics of bacteria. In the present study, the ability of microorganisms to use various organic substances as carbon and nitrogen sources was investigated.

The physiological and biochemical properties of the microorganisms isolated from natural sources are presented in Table 2. Isolate A (*B. subtilis*) ferments D-glucose, D-mannitol, D-maltose, D-lactose, D-sucrose, starch. Isolate B (*P. glabrum*) and isolate C (*P. lagena*) actively ferment glycerol, L-arabinose, D-glucose, D-mannose, L-sorbose, dulcitol, inositol, D-mannitol, D-sorbitol, methyl- α D-mannopyranoside, methyl- α D-glucopyranoside, salicin, D-cellobiose, D-maltose, D-lactose, D-sucrose, D-trehalose, D-raffinose, and starch. Isolate E (*P. ochrochloron*) and isolate F (*L. lactis*) ferment, D-glucose, D-fructose, D-mannose, esculin, D-maltose, D-lactose, D-melibiose, D-sucrose, D-trehalose. Isolate G (*L. plantarum*) ferments L-arabinose, D-glucose, D-fructose, D-mannose, D-mannitol, amygdalin, esculin, salicin, D-cellobiose, D-sucrose, D-trehalose, D-raffinose, gentiobiose, potassium gluconate, potassium 2-ketogluconate. Isolates H and J ferment L-arabinose, D-xylose, D-glucose, D-fructose, D-mannose, D-mannitol, amygdalin, esculin, salicin, D-cellobiose, D-lactose, D-melibiose, D-sucrose, D-trehalose, D-raffinose, gentiobiose, D-turanose, potassium gluconate.

All microorganisms were isolated using one type of medium under similar conditions, which were optimal for their cultivation. The antimicrobial properties of lactic acid bacteria and other antagonistic microorganisms are presented in Table 3 and Fig. 2.

Data analysis (Fig. 2, Table 3) showed that isolate A (*B. subtilis*) exhibited antimicrobial activity against all pathogenic and opportunistic microorganisms, with the greatest antimicrobial activity against *B. mycoides* (22.0 ± 1.1), *S. enterica* (20.0 ± 1.0), *P. aeruginosa* (20.0 ± 1.0), *A. faecalis*

(20.0 ± 1.0), and *A. flavus* (21.0 ± 1.1). Isolate B (*P. glabrum*) was only slightly active against *S. aureus* (5.0 ± 0.3), *P. vulgaris* (7.0 ± 0.4), and *S. flexneri* (4.0 ± 0.2). Isolate C (*P. lagena*) exhibited moderate to low antimicrobial activity against *E. coli* (6.0 ± 0.3), *S. enterica* (10.0 ± 0.5), *S. flexneri* (8.0 ± 0.4), *A. flavus* (4.0 ± 0.2), and *P. citrinum* (5.0 ± 0.3). Isolate D (*P. koreenis*) exhibited moderate antimicrobial activity against *E. coli* (12.0 ± 0.6), *S. enterica* (5.0 ± 0.3), *S. aureus* (18.0 ± 0.9), *A. faecalis* (17.0 ± 0.9), *P. vulgaris* (15.0 ± 0.8), and *S. flexneri* (10.0 ± 0.5). Isolate E (*P. ochrochloron*) had low antimicrobial activity against *A. faecalis* (6.0 ± 0.3) and *L. monocytogenes* (4.0 ± 0.2). Isolate F (*L. lactis*) exhibited antibacterial activity against all pathogenic and opportunistic bacteria, with the greatest antimicrobial activity against *B. mycoides* (24.0 ± 1.2), *A. flavus* (23.0 ± 1.2), and *S. enterica* (22.0 ± 1.1). Isolate G (*L. plantarum*) showed antibacterial potential against all pathogenic and opportunistic bacteria; its greatest antimicrobial activity was against *L. monocytogenes* (23.0 ± 1.2), *B. mycoides* (22.0 ± 1.1), *A. flavus* (22.0 ± 1.1), and *A. faecalis* (21.0 ± 1.1). Isolate H (*L. mesenteroides*) exhibited antibacterial activity against all pathogenic and opportunistic bacteria; its greatest antimicrobial activity was against *B. mycoides* (22.0 ± 1.1), *L. monocytogenes* (21.0 ± 1.1), and *A. flavus* (21.0 ± 1.1). Isolate I (*P. acidilactici*) showed antibacterial potential against all pathogenic and opportunistic bacteria with the highest antimicrobial activity against *A. flavus* (24.0 ± 1.2), *B. mycoides* (23.0 ± 1.2), *A. faecalis* (21.0 ± 1.1), *S. enterica* (21.0 ± 1.1), and *L. monocytogenes* (21.0 ± 1.1). Isolate J (*L. mesenteroides*) showed antibacterial activity against all pathogenic and opportunistic bacteria with the highest activity against *B. mycoides* (20.0 ± 1.0), *L. monocytogenes* (20.0 ± 1.0), and *A. flavus* (20.0 ± 1.0). Isolate K (*P. pentosaceus*) showed antibacterial activity against all pathogenic and opportunistic bacteria; its greatest antimicrobial activity was against *B. mycoides* (24.0 ± 1.2), *A. flavus* (24.0 ± 1.2), and *A. faecalis* (22.0 ± 1.1). Isolate L (*L. casei*) showed antibacterial potential against all pathogenic and opportunistic bacteria; its greatest antimicrobial activity was against *L. monocytogenes* (22.0 ± 1.1) and *A. flavus* (22.0 ± 1.1). Isolate M (*L. fermentum*) exhibited antibacterial potential against all pathogenic and opportunistic bacteria,

with the greatest antimicrobial activity against *B. mycooides* (21.0 ± 1.1) and *L. monocytogenes* (21.0 ± 1.1). Isolate N (*B. hypermegas*) exhibited moderate antimicrobial activity against *E. coli* (12.0 ± 0.6), *S. enterica* (10.0 ± 0.5), *P. aeruginosa* (14.0 ± 0.7), *A. faecalis* (9.0 ± 0.5), *P. vulgaris* (11.0 ± 0.6), and *S. flexneri* (13.0 ± 0.7). Isolate O (*B. ruminicola*) exhibited moderate antimicrobial activity against *E. coli* (7.0 ± 0.4), *S. enterica* (11.0 ± 0.6), *P. aeruginosa* (12.0 ± 0.6), *A. faecalis* (7.0 ± 0.4), *P. vulgaris* (10.0 ± 0.5) and *S. flexneri* (15.0 ± 0.8). Isolate P (*P. damnosus*) exhibited antibacterial potential against all pathogenic and opportunistic bacteria, with the greatest antimicrobial activity against *B. mycooides* (23.0 ± 1.2), *S. enterica* (22.0 ± 1.1), *S. flexneri* (21.0 ± 1.1), and *A. flavus* (21.0 ± 1.1). Isolate Q (*B. paurosaccharolyticus*) exhibited moderate antimicrobial activity against *E. coli* (15.0 ± 0.8), *S. enterica* (13.0 ± 0.7), *P. aeruginosa* (16.0 ± 0.8), *A. faecalis* (12.0 ± 0.6), *P. vulgaris* (14.0 ± 0.7), and *S. flexneri* (17.0 ± 0.9). Isolate R (*H. profundii*) exhibited moderate antimicrobial activity against *Staphylococcus aureus* (11.0 ± 0.6), *Bacillus mycooides* (14.0 ± 0.7), and *Listeria monocytogenes* (10.0 ± 0.5). Isolate S (*G. stearothermophilus*) exhibited antibacterial potential against all pathogenic and opportunistic bacteria, with the greatest antimicrobial activity against *Aspergillus flavus* (24.0 ± 1.2), *B. mycooides* (22.0 ± 1.1), *S. enterica* (22.0 ± 1.1), and *S. flexneri* (21.0 ± 1.1). Isolate T (*B. caldotenax*) exhibited antibacterial potential against all pathogenic and opportunistic bacteria; the greatest antimicrobial activity was against *S. enterica* (23.0 ± 1.2), *L. monocytogenes* (23.0 ± 1.2), and *A. faecalis* (22.0 ± 1.1).

DISCUSSION

The largest number of strains of lactic acid bacteria and other antagonistic microorganisms were isolated from the soil and natural water bodies (Table 1), including *B. subtilis*, *P. glabrum*, *P. koreensis*, *P. ochrochloron*, *L. mesenteroides*, *P. acidilactici*, *P. pentosaceus*, *B. hypermegale*, *B. ruminicola*, *P. damnosus*, *B. paurosaccharolyticus*, *G. stearothermophilus*, and *B. caldotenax*.

A culture liquid without metabolites of isolated microorganisms, without antimicrobial characteristics, was considered as a control. The antibiotic ciprofloxacin has antimicrobial

properties. Statistical analysis was performed using the nonparametric Kruskal-Wallis test. The median test for two independent samples for each test culture established the presence or absence of antimicrobial characteristics by confirming or refuting the equality of the means in the samples when compared with the antibiotic or control. The absence of statistically significant differences ($p < 0.05$) from the control was considered to be due to the absence of antibacterial characteristics, and the absence of statistically significant differences with the antibiotics was considered as the presence of antibacterial properties. Statistically significant differences between the control and antibiotic groups were interpreted as mild antibacterial characteristics of the isolate (Table 4).

The isolates F–I, K, L, S, and T, which affected all test cultures under consideration, were the most promising for further research. These isolates included both lactic acid bacteria and other microorganisms. All lactic acid bacteria isolated from natural sources exhibited antimicrobial efficacy.

The results of our studies are consistent with those presented by other authors.⁵²⁻⁵⁴ In the present study,⁵² LAB strains were characterized, and their antimicrobial activity was investigated. Of the 800 isolates, 20 inhibited the growth of enterotoxigenic *E. coli* and *S. enterica*. Based on the 16S rRNA sequence analysis, 20 isolates were identified as *L. casei* (7), *L. paracasei* (2), *L. plantarum* (4), *L. rhamnosus* (2), *E. avium* (3), *E. faecium* (1), and *E. lactis* (1). The natural ability of *L. plantarum* and *L. rhamnosus* to inhibit *P. aeruginosa* growth has been established⁵¹. In a previous study,⁵⁴ lactic acid was isolated from 32 samples of lactic acid bacteria, and 13 (13/32) of the best *Lactobacillus* isolates were selected by preliminary selection as potential probiotics with antimicrobial activity against pathogenic bacteria. All *Lactobacillus* isolates were then characterized *in vitro* for their antimicrobial activity against pathogens. The isolates were resistant to all investigated pathogens, including *E. coli* (opportunistic bacterium causing gastroenteritis in humans), *S. enterica* (opportunistic bacterium causing gastroenteritis in humans), *P. vulgaris* (opportunistic bacterium causing acute intestinal

infections in humans), *S. flexneri* (causative agent of bacterial dysentery in humans), and *L. monocytogenes* (causative agent of listeriosis in humans).

CONCLUSIONS

Out of the 20 tested microorganisms, 11 exhibited high antimicrobial activity against all tested strains of pathogenic and opportunistic microorganisms. Among the isolated strains, some demonstrated limited antimicrobial activity against only gram-positive or gram-negative test strains, and this requires further study.

As the number of antibiotic-resistant strains among pathogenic and opportunistic microorganisms continues to grow, the study of bacteriocins that are safe for humans as alternative antimicrobial substances is very timely. Non-toxicity, biological safety, and the possibility of combining bacteriocins with other antimicrobial agents (antibiotics, bacteriophages, etc.) will determine their use alone or combined with drugs for antimicrobial therapy. Bacteriocin production is an important characteristic of lactic acid bacteria strains, which should be considered when developing drugs for correcting dysbiotic conditions. Considering the significant potential of bacteriocins and their growing demand, methods for their selection and subsequent chemical synthesis are currently under development.⁵⁵ Recently, information on the possibility of using bacteriocins to fight oncological diseases has been made available. Research in this direction continues, and several research groups, including ours, are studying the possibility of using bacteriocins in treating oncological and infectious bacterial diseases as an alternative to antibiotics.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHORS' CONTRIBUTION

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This research was funded by The Ministry of Science and Higher Education of the Russian Federation within the framework of the Federal Targeted Program "Research and Development in Priority Areas of Development of the Scientific and Technological Complex of Russia for 2014-2020", Agreement No. 075-02-2018-1934 of December 20, 2018; Agreement No. 075-15-2019-1383 of June 18, 2019 (unique project identifier RFMEFI57418X0207).

DATA AVAILABILITY

All datasets generated or analyzed during this study are included in the manuscript.

ETHICS STATEMENT

Not applicable.

REFERENCES

- Gould IM. Antibiotic resistance: the perfect storm. *Int J Antimicrob Agents*. 2009;34:S2-S5. doi: 10.1016/S0924-8579(09)70549-7
- Xia J, Gao J, Kokudo N, Hasegawa K, Tang W. Methicillin-resistant *Staphylococcus aureus* antibiotic resistance and virulence. *Biosci Trends*. 2013;7:113-121.
- Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections. *Drugs*. 2009;69:1879-1901. doi: 10.2165/11315690-000000000-00000
- Calfee DP. Methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant Enterococci, and other Gram-positives in healthcare. *Curr Opin Infect Dis*. 2012;25:385-394. doi: 10.1097/QCO.0b013e3283553441
- Duval RE, Grare M, Demoré B. Fight against antimicrobial resistance: we always need new antibacterials but for right bacteria. *Molecules*. 2019;24:3152. doi: 10.3390/molecules24173152
- Mazurek-Popczyk J, Pisarska J, Bok E, Baldy-Chudzik K. Antibacterial activity of bacteriocinogenic commensal *Escherichia coli* against zoonotic strains resistant and sensitive to antibiotics. *Antibiotics*. 2020;9(7):411. doi: 10.3390/antibiotics9070411
- Planson AG, Carbonell P, Grigoras I, Faulon JL. Engineering antibiotic production and overcoming bacterial resistance. *Biotechnol J*. 2011;6:812-825. doi: 10.1002/biot.201100085
- Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. *J Antibiot*. 2013;66:571-591. doi: 10.1038/ja.2013.86
- Mbaveng AT, Sandjo LP, Tankeo SB, et al. Antibacterial activity of nineteen selected natural products against multidrug resistant Gram-negative phenotypes. *SpringerPlus*. 2015;4:823. doi: 10.1186/s40064-015-1645-8
- Gratia A. Sur un remarquable exemple d'antagonisme entre deux souches de coillabacille. *CR Seances Soc Biol*

- Fil.* 1925;93:1040-1041.
11. Akerey B, Le-Lay C, Fliss I, Subirade M, Rouabhia M. In vitro efficacy of nisin Z against *Candida albicans* adhesion and transition following contact with normal human gingival cells. *J Appl Microbiol.* 2009;107:1298-1307. doi: 10.1111/j.1365-2672.2009.04312.x
 12. Hassan M, Kjos M, Nes IF, Diep DB, Lotfipour F. Natural antimicrobial peptides from bacteria: Characteristics and potential applications to fight against antibiotic resistance. *J Appl Microbiol.* 2012;113:723-736. doi: 10.1111/j.1365-2672.2012.05338.x
 13. Torres NI, Noll KS, Xu S, et al. Safety, formulation and in vitro antiviral activity of the antimicrobial peptide subtilisin against herpes simplex virus type 1. *Probiotics Antimicrob Proteins.* 2013;5:26-35. doi: 10.1007/s12602-012-9123-x
 14. Park SC, Park Y, Hahn KS. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. *Int J Mol Sci.* 2011;12:5971-5992. doi: 10.3390/ijms12095971
 15. Yasir M, Willcox MDP, Dutta D. Action of antimicrobial peptides against bacterial biofilms. *Materials.* 2018;11:2468. doi: 10.3390/ma11122468
 16. Cascales E, Buchanan SK, Duché D, et al. Colicin biology. *Microbiol Mol Biol Rev.* 2007;71:158-229. doi: 10.1128/MMBR.00036-06
 17. Martínez B, Rodríguez A, Suárez E. Antimicrobial peptides produced by bacteria: the bacteriocins. In Villa TG, Vinas M (eds.), *New weapons to control bacterial growth.* Springer International Publishing, Cham, Switzerland, 2016:15-38. doi: 10.1007/978-3-319-28368-5_2
 18. Ikryannikova LN, Kurbatov LK, Gorokhovets NV, Zamyatin AA Jr. Contact-dependent growth inhibition in bacteria: do not get too close! *Int J Mol Sci.* 2020;21(21):7990. doi: 10.3390/ijms21217990
 19. Cotter PD, Ross RP, Hill C. Bacteriocins - A viable alternative to antibiotics? *Nat Rev Microbiol.* 2013;11:95-105. doi: 10.1038/nrmicro2937
 20. Heng NCK, Wescombe PA, Burton JP, Jack RW, Tagg JR. The diversity of bacteriocins in gram-positive bacteria. In Riley MA, Chavan MA (eds.), *Bacteriocins: ecology and evolution.* Springer Berlin Heidelberg, Berlin/Heidelberg, Germany, 2007:45-92. doi: 10.1007/978-3-540-36604-1_4
 21. Perez RH, Zendo T, Sonomoto K. Novel bacteriocins from lactic acid bacteria (LAB): Various structures and applications. *Microb Cell Factories.* 2014;13:53. doi: 10.1186/1475-2859-13-S1-S3
 22. Yang SC, Lin CH, Sung CT, Fang JY. Antibacterial activities of bacteriocins: Application in foods and pharmaceuticals. *Front Microbiol.* 2014;5:241. doi: 10.3389/fmicb.2014.00241
 23. Kleinkauf H, von Döhren H. Review nonribosomal biosynthesis of peptide antibiotics. In Christen P, Hofmann E (eds.), *EJB Reviews 1990.* Springer, Berlin/Heidelberg, Germany, 1990:151-165. doi: 10.1007/978-3-642-76168-3_11
 24. Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. *Microbiol Mol Biol Rev.* 1995;59:171-200. doi: 10.1128/MMBR.59.2.171-200.1995
 25. Chavan MA, Riley MA. Molecular evolution of bacteriocins in gram-negative bacteria. In Riley MA, Chavan MA, editors. *Bacteriocins: ecology and evolution.* Springer, Berlin/Heidelberg, Germany, 2007:19-43. doi: 10.1007/978-3-540-36604-1_3
 26. Klaenhammer TR. Bacteriocins of lactic acid bacteria. *Biochimie.* 1988;70:337-349. doi: 10.1016/0300-9084(88)90206-4
 27. O'Connor PM, O'Shea EF, Guinane CM, O'Sullivan O, Cotter PD, Ross RP, Hill C. Nisin H is a new nisin variant produced by the gut-derived strain *Streptococcus hyointestinalis* DPC6484. *Appl Environ Microbiol.* 2015;81:3953-3960. doi: 10.1128/AEM.00212-15
 28. Majeed H, Lampert A, Ghazaryan L, Gillor O. The weak shall inherit: bacteriocin-mediated interactions in bacterial populations. *PLoS ONE.* 2013;8:e63837. doi: 10.1371/journal.pone.0063837
 29. Cintas LM, Casaus MP, Herranz C, Nes IF, Hernández PE. Review: bacteriocins of lactic acid bacteria. *Food Sci Technol Int.* 2001;7:281-305. doi: 10.1106/R8DE-P6HU-CLXP-5RYT
 30. Simons A, Alhanout K, Duval RE. Bacteriocins, antimicrobial peptides from bacterial origin: overview of their biology and their impact against multidrug-resistant bacteria. *Microorganisms.* 2020;8(5):639. doi: 10.3390/microorganisms8050639
 31. Balciunas EM, Castillo Martinez FA, Todorov SD, de Melo Franco BDG, Converti A, de Souza Oliveira RP. Novel biotechnological applications of bacteriocins: A review. *Food Control.* 2013;32:134-142. doi: 10.1016/j.foodcont.2012.11.025
 32. Deegan LH, Cotter PD, Hill C, Ross P. Bacteriocins: Biological tools for bio-preservation and shelf-life extension. *Int Dairy J.* 2006;16:1058-1071. doi: 10.1016/j.idairyj.2005.10.026
 33. Zacharof MP, Lovitt RW. Bacteriocins produced by lactic acid bacteria a review article. *APCBE Procedia.* 2012;2:50-56. doi: 10.1016/j.apcbee.2012.06.010
 34. Abee T, Krockel L, Hill C. Bacteriocins: Modes of action and potentials in food preservation and control of food poisoning. *Int J Food Microbiol.* 1995;28:169-185. doi: 10.1016/0168-1605(95)00055-0
 35. Ahmad V, Khan MS, Jamal QMS, Alzohairy MA, Al Karaawi MA, Siddiqui MU. Antimicrobial potential of bacteriocins: In therapy, agriculture and food preservation. *Int J Antimicrob Agents.* 2017;49:1-11. doi: 10.1016/j.ijantimicag.2016.08.016
 36. Barbosa AAT, Mantovani HC, Jain S. Bacteriocins from lactic acid bacteria and their potential in the preservation of fruit products. *Crit Rev Biotechnol.* 2017;37:852-864. doi: 10.1080/07388551.2016.1262323
 37. Rea MC, Sit CS, Clayton E, et al. A posttranslationally modified bacteriocin with a narrow spectrum of activity against *Clostridium difficile*. *Proc Natl Acad Sci USA.* 2010;107:9352-9357. doi: 10.1073/pnas.0913554107
 38. Molloy EM, Ross RP, Hill C. 'Bac' to the future: Bioengineering antibiotics for designer purposes. *Biochem Soc Trans.* 2012;40:1492-1497. doi: 10.1042/BST20120193
 39. Settanni L, Corsetti A. Application of bacteriocins in vegetable food biopreservation. *Int J Food Microbiol.* 2008;121:123-338. doi: 10.1016/j.

- ijfoodmicro.2007.09.001
40. Santos JCP, Sousa RCS, Otoni CG, et al. Nisin and other antimicrobial peptides: Production, mechanisms of action, and application in active food packaging. *Innov Food Sci Emerg Technol*. 2018;48:179-194. doi: 10.1016/j.ifset.2018.06.008
 41. Chen H, Hoover DG. Bacteriocins and their food applications. *Compr Rev Food Sci Food Saf*. 2003;2:82-100. doi: 10.1111/j.1541-4337.2003.tb00016.x
 42. Beshkova D, Frengova G. Bacteriocins from lactic acid bacteria: Microorganisms of potential biotechnological importance for the dairy industry. *Eng Life Sci*. 2012;12:419-432. doi: 10.1002/elsc.201100127
 43. Singh N, Abraham J. Ribosomally synthesized peptides from natural sources. *J Antibiot*. 2014;67:277-289. doi: 10.1038/ja.2013.138
 44. Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. *Front Public Health*. 2014;2:145. doi: 10.3389/fpubh.2014.00145
 45. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. *Nat Rev Microbiol*. 2011;9:894-896. doi: 10.1038/nrmicro2693
 46. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. *Drug Resist Updat*. 2011;14:118-124. doi: 10.1016/j.drug.2011.02.003
 47. Toussaint KA, Gallagher JC. β -Lactam/ β -Lactamase inhibitor combinations: from then to now. *Ann Pharmacother*. 2015;49:86-98. doi: 10.1177/1060028014556652
 48. Allen HK, Trachsel J, Looft T, Casey TA. Finding alternatives to antibiotics. *Ann NY Acad Sci*. 2014;1323:91-100. doi: 10.1111/nyas.12468
 49. Tenea GN, Hurtado P, Ortega C. A novel weissella cibaria strain utngt21o isolated from wild solanum quitoense fruit: genome sequence and characterization of a peptide with highly inhibitory potential toward gram-negative bacteria. *Foods*. 2020;9(9):1242. doi: 10.3390/foods9091242
 50. Zimina M, Babich O, Prosekov A, et al. Overview of global trends in classification, methods of preparation and application of bacteriocins. *Antibiotics*. 2020;9(9):553. doi: 10.3390/antibiotics9090553
 51. Prosekov AY, Dyshlyuk LS, Milentyeva IS, et al. Antioxidant and antimicrobial activity of bacteriocin-producing strains of lactic acid bacteria isolated from the human gastrointestinal tract. *Progress in nutrition*. 2017;19(1):67-80.
 52. Wang X, Wang W, Lv H, et al. Probiotic potential and wide-spectrum antimicrobial activity of lactic acid bacteria isolated from Infant Feces. *Probiotics & Antimicro Prot*. 2021;13:90-101. doi: 10.1007/s12602-020-09658-3
 53. Chappell TC, Nair NU. Engineered lactobacilli display anti-biofilm and growth suppressing activities against *Pseudomonas aeruginosa*. *NPJ Biofilms Microbiomes*. 2020;6:48. doi: 10.1038/s41522-020-00156-6
 54. Prabhurajeshwar C, Chandrakanth K. Evaluation of antimicrobial properties and their substances against pathogenic bacteria in-vitro by probiotic Lactobacilli strains isolated from commercial yoghurt. *Clin Nutr Exp*. 2019;23:97-115. doi: 10.1016/j.yclnex.2018.10.001
 55. Zaslavskaya MI, Makhrova TV, Aleksandrova NA, et al. Prospects for using bacteriocins of normal microbiota in antibacterial therapy (review). *Bacteriocins of Microbiota and Antibiotic Therapy*. 2019;11(3):136-144. doi: 10.17691/stm2019.11.3.17